Last viewed: INBX

Prices are updated after-hours

INBX

Inhibrx, Inc.

INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

(0.0% 1d) (-2.0% 1m) (72.3% 1y) (0.0% 2d) (0.7% 3d) (0.2% 7d) (-39.08% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,629,589,290
http://www.inhibrx.com
Sec Filling | Patents | 95 employees

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

infectious disease

add to watch list Paper trade email alert is off

Press-releases

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
Published: 2024-03-26 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

|

Health Technology

| -5.96% | O: -0.26% H: 0.0% C: 0.0%
TGAN | $4.83 -0.41% -0.41% 200K

|

| -1.43% | O: 0.2% H: 0.0% C: -0.2%
FREE | $4.815 -0.1% -0.1% 180K

|

Consumer Non-Durables

| 0.0% | O: 0.0% H: 0.21% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -3.57% | O: 1.06% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| -1.97% | O: 0.29% H: 0.23% C: -0.06%
HMST | $12.2 -5.94% -6.31% 170K

|

| -19.8% | O: 0.26% H: 0.07% C: -0.85%
EVBG | $34.9 0.0% 580K

|

Technology Services

| 0.29% | O: 0.09% H: 0.03% C: -0.03%

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN
Published: 2024-03-12 (Crawled : 03:00) - prnewswire.com
JNPR | $35.36 -1.45% 0.0% 5.3M

|

Technology Services

| -4.43% | O: 0.38% H: 0.08% C: -0.78%
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -1.84% | O: 0.01% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| -2.22% | O: 0.26% H: 0.21% C: -0.03%
HAYN | $60.38 -0.15% -0.15% 140K

|

Non-Energy Minerals

| 1.58% | O: -0.03% H: 0.19% C: 0.0%

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Published: 2024-02-28 (Crawled : 19:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -1.87% | O: -0.63% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| -13.09% | O: -0.86% H: 0.13% C: -5.66%
year financial results

Acadia Announces Additions to Executive Team - Jan 31, 2024
Published: 2024-01-31 (Crawled : 10:00) - biospace.com/
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| -11.28% | O: -0.36% H: 0.57% C: -0.21%
EXEL | $23.7 1.76% 1.73% 1.5M

|

Health Technology

| 8.31% | O: 0.18% H: 0.55% C: -0.78%
ACAD | News | $16.57 -1.02% -1.03% 1.3M

|

Health Technology

| -38.17% | O: -0.71% H: 0.71% C: -2.74%

Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
NS | $22.55 -0.71% 0.0% 630K

|

Distribution Services

| 5.77% | O: -0.09% H: 0.47% C: -1.22%
ADM | $61.56 -0.37% -0.6% 3.7M

|

Process Industries

| 19.09% | O: 1.04% H: 3.75% C: 0.15%
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -7.21% | O: -2.05% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 3.15% | O: 6.51% H: 4.73% C: 2.25%
sanofi

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Published: 2024-01-23 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -7.21% | O: -2.05% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 3.15% | O: 6.51% H: 4.73% C: 2.25%
rare disease pipeline acquire potential sanofi

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Published: 2024-01-23 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -7.21% | O: -2.05% H: 0.0% C: 0.0%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 3.15% | O: 6.51% H: 4.73% C: 2.25%
inbrx-101 sanofi

Navigating the Complex Market Landscape of Rare Genetic Disorders: A Deep Dive into Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AATD) | DelveInsight
Published: 2023-11-09 (Crawled : 22:00) - prnewswire.com
ATXS | $9.02 -6.43% -6.87% 660K

|

| 93.97% | O: 0.43% H: 0.86% C: -1.29%
OPK | $1.225 -2.0% -2.04% 6.1M

|

Health Technology

| -3.91% | O: 1.56% H: 0.0% C: -3.08%
IONS | $42.455 1.47% 1.45% 730K

|

Health Technology

| -10.27% | O: 0.53% H: 0.38% C: -2.52%
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 87.87% | O: 0.98% H: 5.52% C: 3.35%
INCY | $51.72 0.14% 0.14% 1.5M

|

Health Technology

| -1.49% | O: 0.4% H: 0.0% C: -0.55%
rare genetic market

Inhibrx Announces Participation in Upcoming Scientific Conferences
Published: 2023-10-18 (Crawled : 20:00) - prnewswire.com
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 100.47% | O: 0.17% H: 0.0% C: -7.97%

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
Published: 2023-09-19 (Crawled : 20:00) - prnewswire.com
INBX | $34.385 0.75% 0.74% 220K

|

Health Technology

| 65.69% | O: -0.1% H: 2.75% C: -5.69%
inbrx-101 treatment canada

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001739614-24-000019	4	2024-03-22	2024-03-22	Sell	M	110	18020
0001739614-24-000019	4	2024-03-22	2024-03-21	Sell	M	3113	18130
0001739614-24-000019	4	2024-03-22	2024-03-20	Sell	M	16777	21243

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M

|

Consumer Services

BOF | $1.99 70.09% 41.21% 110M

|

ILAG | $0.51 6.03% 40.62% 1.7M

|

LICN | $0.941 68.04% 40.49% 15M

|

AMST | $3.31 65.5% 39.58% 70M

|

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M

|

Technology Services

WIMI | $1.15 58.53% 36.92% 19M

|

Technology Services

AIH | $0.45 12.5% 30.92% 320K

|

Health Services

MULN | News | $3.78 38.46% 27.78% 13M

|

RILY | $29.86 37.48% 27.26% 12M

|

Last 48 Hours Insiders Buying

RKT P 347 | $12.55 -0.63% 0.48% 1.7M

|

| 22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K

|

| 22:00
TGEN P 10000 | $0.685 39.71% 6.6K

|

| 20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K

|

| 15:30
RMCF | $3.54 0.28% 7.1K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar